INTRODUCTION AND OBJECTIVES:
To compare perioperative and oncologic outcomes between Partial nephrectomy (PN) and Cryoablation (CA).
METHODS: We undertook propensity score match (Age, ASA score, tumor size, PADUA score) analysis of patients who underwent CA (percutaneous or laparoscopic) or PN (laparoscopic or robotic). Clinicopathologic and perioperative outcomes were compared. To assess the Disease-free survival and cancer specific survival, patients with diagnosis of oncocytoma were excluded from final analysis.
RESULTS: Overall, data from 164 patients who underwent CA (82 patients) or PN (82 patients) were analyzed. Clinicopathological and post-operative outcomes of patients are reported in table 1a. The two groups were similar regarding sex, age, ASA score, clinical tumor size, PADUA risk group and histology. Preoperative creatinine was lower in the PN group (p[0.004). Post-operative complications rate was similar between the two groups. Mean follow up was 34 months for the PN group and 54 months in the CA group (p<0.001). Mean serum creatinine variation was significantly higher in the PN (þ0.1mg/dL) group than in the CA (þ0.002 mg/dL) group (p<0.001) Overall, local recurrence occurred in 14 (10%) patients, 3 (4%) in the PN group and 11 (15%) in the CA group (Fig 1a) , respectively (p[0.03). At univariable analysis main predictors of recurrence were intermediate/high PADUA risk group and CA (Tab 1b).
CONCLUSIONS: In our propensity score match analysis, PN provides better cancer control then CA at the cost of little but significant impairment of renal function. Particularly in elderly patients, the selection of the best treatment is crucial to find the optimal balance between the cancer control and treatment's related morbidity. is an emerging ablative technology that applies high voltage, short pulse electrical current to create cellular membrane nanopores and cause apoptosis. This is thought to improve on the thermal limitations of other ablative modalities. We report the oncologic outcomes of percutaneous IRE for small renal masses after 5 years.
METHODS: A single institution retrospective review of cT1a renal masses patients treated with IRE from April 2013 through August 2018 was performed. Small, low complexity tumors were generally selected for IRE using the NanoKnifeÓ System (Angiodynamics, Latham, NY). Renal mass biopsy was obtained prior to or during ablation in most circumstances. Biopsy was excluded at ablation in some patients due to clinician concern IRE probe displacement. Postablation guideline-based surveillance imaging was performed. Survival analysis was performed via the Kaplan-Meier method.
RESULTS: IRE was performed on 45 tumors in 44 patients. Mean tumor size was 2.0 AE 0.6 cm with a median nephrometry score of 5 (Table 1) . Thirty-one (69%) tumors were biopsied either preprocedure or intraoperatively and 26 (58%) confirmed malignancy. Thirty-three patients (73%) were post-procedure same day discharges. No Clavien Grade III or higher intraoperative or postoperative complications occurred. Initial treatment success rate was 94%. Three initial treatment failures (6%) underwent successful salvage radiofrequency ablation. With 24-month median follow-up, three-year local recurrence-free survival was 85% in biopsy confirmed renal cell carcinoma (RCC) patients and 90% in all patients (Figure 1) . Three-year overall survival was 100% in RCC confirmed patients and 97% in all patients. There were no RCC related deaths.
CONCLUSIONS: IRE has low morbidity and reasonable moderate-term oncologic results in small, low complexity tumors. Larger series and longer follow-up in a more heterogeneous cohort is needed to evaluate treatment durability. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e921
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